NCT01155817View on ClinicalTrials.gov

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Bone Marrow Transplant FailureLymphoma, Non-HodgkinLymphoma, T-Cell, Peripheral
Interventions
DRUG

Nilotinib

200, 400, 800, oral

Trial Locations (5)

14263

Roswell Park Cancer Institute, Buffalo

80218

Colorado Blood Cancer Institute, Denver

94305

Stanford University School of Medicine, Stanford

98109-1024

Fred Hutchinson Cancer Research Center, Seattle

V5Z1M9

Gordon and Leslie Diamond Health Care Centre Hematology Administration, Vancouver

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Stanford University

OTHER